Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 6/2024

Open Access 16-03-2024 | Spondyloarthropathy | Review

JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance

Authors: Siba P. Raychaudhuri, Ruchi J. Shah, Sneha Banerjee, Smriti K. Raychaudhuri

Published in: Current Rheumatology Reports | Issue 6/2024

Login to get access

Abstract

Purpose of Review

Janus kinase–signal transducers and activators of transcription cell signaling proteins (JAK-STATs) play a key regulatory role in functioning of several inflammatory cytokines. JAK-STAT signaling proteins are the key regulators of the cytokine/cytokine receptor system involved in the pathogenesis of various autoimmune disease including spondyloarthritis (SpA). This article mainly highlights the JAK-STAT signaling system, its association with the relevant cytokine/cytokine-receptor system, and its regulatory role in pathogenesis of SpA. Also, we have briefly addressed the principle for the use JAKi in SpA and the current status of use of JAK inhibitors (JAKi) in SpA.

Recent Findings

Recent developments with newer JAK molecules as well as other molecules beyond JAK inhibitors are now an exciting field for the development of novel therapies for autoimmune diseases and various malignant conditions. In this article, we have provided a special emphasis on how various cell signaling systems beyond JAK/STAT pathway are relevant to SpA and have provided a comprehensive review on this upcoming field in respect to the novel TYK2 inhibitors, RORγT inhibitors, mTOR inhibitors, NGF inhibitors, and various STAT kinase inhibitors.

Summary

SpA are a group of autoimmune diseases with multifactorial etiologies. SpA is linked with genetic predisposition, environmental risk factors, and the immune system-mediated systemic inflammation. Here, we have provided the regulatory role of JAK/STAT pathway and other intracellular signaling system in the pathogenesis of SpA and its therapeutic relevance.
Literature
1.
Raychaudhuri S, Cheema KS, Raychaudhuri SK, Raychaudhuri SP. Janus kinase-signal transducers and activators of transcription cell signaling in spondyloarthritis: rationale and evidence for JAK inhibition. Curr Opin Rheumatol. 2021;33(4):348–55.CrossRefPubMed
2.
• Akkoc N, Khan MA. JAK inhibitors for axial spondyloarthritis: what does the future hold? Curr Rheumatol Rep. 2021;23(6):34. A comprehensive review on JAK inhibitors (JAKis) as a new therapeutic class for the treatment of axial spondyloarthritis.
3.
Villarino AV, Gadina M, O’shea JJ, SnapShot Kanno Y. Jak-STAT signaling II. Cell. 2020;181(7):1696-1696.e1.CrossRefPubMed
4.
• Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford) 2019;58 (Suppl 1): i4-i16. An excellent review on JAK/STAT kinase system and its regulatory role on inflammatory diseases; as well as the prospects and challenges ahead in targeting JAKs.
5.
Shah RJ, Raychaudhuri Banerjee S, S, Raychaudhuri SP. JAK-STAT inhibitors in immune mediated diseases: an overview. Indian J Dermatolo Venereol Leprol. 2023;89:691–9.
6.
Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57:5023–38.CrossRefPubMed
7.
Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020;6(3):e001374.CrossRefPubMedPubMedCentral
8.
Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87.CrossRefPubMed
9.
Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus Kinase inhibitors in the treatment of autoimmune and inflammatory disease. J Allergy Clin Immunol. 2021;147(3):814–26.CrossRefPubMed
10.
Kundu-Raychaudhuri S, Abria C, Raychaudhuri SP. IL-9, a local growth factor for synovial T cells in inflammatory arthritis. Cytokine. 2016;79:45–51.CrossRefPubMed
11.
Chen C, Zhang X, Wang Y. Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population. Clin Immunol. 2010;136:442–6.CrossRefPubMed
12.
•• Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT Kinase signaling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis. 2017;76(10):e36. A key article describing the functional significance of the JAK STAT kinase signaling system in the pathogenesis of psoriatic arthritis and its relevance for developing novel therapies for spondyloarthritis by targeting this kinase pathway.CrossRefPubMed
13.
Maeda Y, Huang T, Manning C, et al. Blockade of the JAK/STAT pathway inhibits inflammation and bone formation in two murine models of spondyloarthritis. Arthritis Rheumatol 2018; 70 (Suppl 10) 1
14.
Gracey E, Hromadova D, Lim M, et al. TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. J Clin Invest. 2020;130:1863–78.CrossRefPubMedPubMedCentral
15.
Deodhar A, van der Heijde D, Sieper J, et al. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol. 2022;74:70–80.CrossRefPubMed
16.
Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400:369–79.CrossRefPubMed
17.
Baraliakos X, van der Heijde D, Sieper J, et al. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Res Ther. 2023Sep 18;25(1):172.CrossRefPubMedPubMedCentral
18.
Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021Aug;80(8):1004–13.CrossRefPubMed
19.
van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2378–87.CrossRefPubMed
20.
•• Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020;79:760–70. This article provides a systematic literature review (SLR) about the safety of synthetic (s) including JAKi and biologics (b) disease-modifying anti-rheumatic dugs (DMARDs).
21.
Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253–62.CrossRefPubMed
22.
Genovese MC, Smolen J, Takeuchi T, et al. FRI0123: safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis. Ann Rheum Dis. 2020;79(Suppl 1):638.CrossRef
23.
Cohen SB, van Vollenhoven R, Curtis JR, et al. THU0187: safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79(Suppl. 1):315.
24.
Curtis JR, Xie F, Yun H, et al. Real world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843.CrossRefPubMed
25.
Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960.CrossRefPubMedPubMedCentral
26.
Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89.CrossRefPubMedPubMedCentral
27.
Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675.CrossRefPubMedPubMedCentral
28.
Curtis JR, Xie F, Yang S, et al. Risk for herpes zoster in tofacitinib-treated glucocorticoids. Arthritis Care Res. 2019;71:1249–54.CrossRef
29.
Desai RJ, Pawar A, Weinblatt ME, et al. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study. Arthritis Rheumatol. 2019;71:892–900.CrossRefPubMed
30.
Ytterberg SR, Bhatt DL, Mikuls TR, ORAL Surveillance Investigators, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.
31.
Hromadová D, Elewaut D, Inman RD, et al. From science to success? Targeting tyrosine kinase 2 in spondyloarthritis and related chronic inflammatory diseases. Front Genet. 2021;5(12):685280.CrossRef
32.
•• Gonciarz M, Pawlak-Buś K, Leszczyński P, Owczarek W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy.  2021;3(13):1135–1150. Here the authors review the evidence for targeting TYK2 as a more specific approach to treating these conditions. TYK2 inhibitors are clinically effective in autoimmune and inflammatory diseases and may avoid some of the complications reported with nonselective JAK inhibitors.
33.
Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379:1313–21.CrossRefPubMed
34.
Raychaudhuri SP, Raychaudhuri SK, et al. Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum. 2011;63(11):3243–52.CrossRefPubMed
35.
Tive L, Bello AE, Radin D, et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019;12:975–95.CrossRefPubMedPubMedCentral
36.
Datta-Mitra A, Kundu-Raychaudhuri S, Mitra A, et al. Cross talk between neuroregulatory molecule and monocyte: nerve growth factor activates the inflammasome. PLoS ONE. 2015Apr 15;10(4):e0121626.CrossRefPubMedPubMedCentral
37.
C. Buerger. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target. Front. Immunol. 2018: 9(2786).
38.
Raychaudhuri SK, Raychaudhuri SP. mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target. Indian J Dermatol. 2014;59(1):67–70.CrossRefPubMedPubMedCentral
39.
Chen S, van Tok MN, Knaup VL, et al. mTOR blockade by rapamycin in SpA: impact on inflammation and new bone formation in vitro and in vivo. Front Immunol. 2020;27(10):2344.CrossRef
40.
Pandya VB, Kumar S, Sachchidanand, et al. Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-γ (RORγ or RORc) inhibitors: hits and misses. J Med Chem. 2018;61(24):10976–95.
41.
Guendisch U, Weiss J, Ecoeur F, et al. Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo. PLoS ONE. 2017;12(11):e0188391.CrossRefPubMedPubMedCentral
42.
Gege C. RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from vitae pharmaceuticals: patent evaluation of WO2016061160 and US20160122345. Expert Opin Ther Pat. 2017;27(1):1–8.CrossRefPubMed
43.
Liu X, Lee YS, Yu CR, Egwuagu CE. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol. 2008;180(9):6070–6.CrossRefPubMed
44.
Liang Y, Pan HF, Ye DQ. Therapeutic potential of STAT4 in autoimmunity. Expert Opin Ther Targets. 2014;18(8):945–60.CrossRefPubMed
45.
Huda N, Hosen MdI, Yasmin T, Sarkar PK, Hasan AK, Nabi AH. Genetic variation of the transcription factor GATA3, not STAT4, is associated with the risk of type 2 diabetes in the Bangladeshi population. PLoS ONE. 2018;13(7):e0198507.CrossRefPubMedPubMedCentral
46.
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–36.CrossRefPubMed
47.
Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80:312–20.CrossRefPubMed
48.
Mease PJ, Deodhar A, Heijde DVD, et al. POS0198 efficany and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled. Ann Rheum Dis. 2021;80(Suppl 1):314–5.
49.
Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2367–77.CrossRefPubMed
Metadata
Title
JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance
Authors
Siba P. Raychaudhuri
Ruchi J. Shah
Sneha Banerjee
Smriti K. Raychaudhuri
Publication date
16-03-2024
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 6/2024
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-024-01144-x
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits